Pharmacogenetic (PGx) testing laboratories are tasked with quickly analyzing samples and reporting results. It can be a challenge to accurately characterize samples or even to generate results. Labs are often required to analyze challenging samples with low-quality DNA. Increased prevalence of self-collection exacerbates the issue as samples are collected at home or in an off-site location and mailed to the laboratory.
Additionally, it is estimated that up to 13% of the general population possesses a CYP2D6 hybrid allele. These unique rearrangements often go undetected when samples are characterized using common PGx testing methods. Hybrid alleles render the CYP2D6 gene non-functional. Not detecting them can lead to mischaracterization of drug metabolism status.
This webinar focuses on how PGx testing labs can respond to these common challenges and accurately characterize samples.
- Common PGx testing challenges including low-quality DNA and CYP2D6 hybrid alleles
- How common challenges lead to sample mischaracterization
- Testing methods to respond to these challenges and deliver accurate results
Robin Everts, PhD, Staff Scientist, Scientific Affairs, Agena Bioscience
Recorded on June 215, 2019
Learn more about our pharmacogenetics solutions.